Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Future Directions in the Treatment of Advanced or Recurrent Endometrial Cancer

December 20th 2023

Experts are enthusiastic about the potential of antibody drug conjugates to de-escalate therapy and reduce toxicity in advanced and recurrent endometrial cancer treatment, with a focus on the importance of diversity plans in clinical trials to ensure broader applicability.

Recent Data on Anti-TROP2 ADCs for Patients With Advanced or Recurrent Endometrial Cancer

December 20th 2023

The panel highlights recent data on antibody drug conjugates targeting TROP2 in patients with advanced or recurrent endometrial cancer and the need for dose optimization.

Individual Disease Histology and Local Control Are Key Considerations in Endometrial Cancer Care

December 18th 2023

Hope Cottrill, MD, highlights practice-changing developments in endometrial cancer care, the benefits of local control with radiation in patients with locally aggressive disease, and questions that remain regarding treatment sequencing with immunotherapy.

The TROPiCS-03 Study: Sacituzumab Govitecan in Patients With Advanced Endometrial Cancer

December 18th 2023

Floor Backes, MD, and Matthew Powell, MD, review data on sacituzumab govitecan, an antibody-drug conjugate targeting topoisomerase in patients with advanced endometrial cancer.

Adverse Events Seen With Systemic Therapies in Patients With Advanced Endometrial Cancer

December 18th 2023

Drs Backes and Powell discuss the management of adverse events between upfront immunotherapy versus chemotherapy followed by later immunotherapy for endometrial cancer, noting the need for molecular subgroup data from trials like LEAP-001.

Pembrolizumab Plus Lenvatinib Misses Both Survival End Points in Advanced, Recurrent Endometrial Cancer

December 15th 2023

The combination of pembrolizumab and lenvatinib failed to produce a statistically significant improvement in progression-free survival and overall survival vs platinum-based chemotherapy with carboplatin and paclitaxel as frontline therapy in patients with advanced or recurrent endometrial cancer whose disease in mismatch repair proficient/not microsatellite instability–high or mismatch repair deficient.

Dostarlimab Plus Chemo Granted EU Approval for dMMR/MSI-H Endometrial Cancer

December 14th 2023

The European Commission has granted marketing authorization to dostarlimab paired with carboplatin and paclitaxel in adults with dMMR/MSI-H primary advanced or recurrent endometrial cancer who are eligible to receive systemic treatment.

Advances in Anti-HER2 ADCs in Patients With Advanced or Recurrent Endometrial Cancer

December 13th 2023

Key opinion leaders share excitement about antibody-drug conjugates targeting HER2 in advanced or recurrent endometrial cancer, and debate optimal HER2 testing methods, with some preferring gastric cancer scoring criteria over breast cancer criteria.

Emerging Data on Combination Therapies in Advanced or Recurrent Endometrial Cancer

December 13th 2023

The panel reviews results from the ATTEND and DUO-E trials in advanced endometrial cancer, suggesting pembrolizumab remains the standard for the dMMR patient subset while combinations with PARP inhibitors may improve outcomes in pMMR.

The Impact of Real-World Evidence on the Treatment of Patients With Advanced Endometrial Cancer

December 11th 2023

Matthew Powell, MD, and Floor Backes, MD, discuss real-world evidence from recent trials confirming benefit of immunotherapies in practice for patients with advanced endometrial cancer.

Data From the AtTEnd: Study: Atezolizumab Plus Carboplatin and Paclitaxel for Treatment of Advanced Endometrial Cancer

December 11th 2023

Drs Powell and Backes discuss additional immunotherapy trial results from ESMO 2023 including AtTEnd and DUO-E, noting differences across trials likely due to patient population composition rather than drug differences, and need for caution with PARP inhibitor maintenance.

The NRG-GY018 Trial: Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer

December 6th 2023

Dr Thomas C. Krivak highlights key data from the GY018 trial investigating chemotherapy plus pembrolizumab in both dMMR and pMMR advanced endometrial cancer, confirming and extending the findings from the RUBY trial supporting pembrolizumab's approval and use in both dMMR and pMMR populations.

Dostarlimab Plus Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Cancer: Data from the RUBY Trial

December 6th 2023

Thomas C. Krivak, MD, shares the positive results from the RUBY trial of pembrolizumab plus chemotherapy followed by maintenance in patients with dMMR advanced endometrial cancer, supporting its approval and use in this population.

Dostarlimab Plus Chemotherapy for the Treatment of Advanced Endometrial Cancer: Data from the RUBY Trial

December 4th 2023

Matthew Powell, MD, and Floor Backes, MD, enthusiastically discuss the practice-changing RUBY trial results presented at the 2023 ESMO Congress showing impressive survival benefits with immunotherapy plus chemotherapy for both MMR-deficient and MMR-proficient advanced endometrial cancer.

Diversity and Access to Clinical Trials in Endometrial Cancer

December 4th 2023

Experts Ritu Salani, MD, MBA, and Bhavana Pothuri, MD, explore the significance of enrolling diverse patients in clinical trials and the pivotal role of community settings in advancing endometrial cancer research and treatment.

Current Data on Single-Agent Immunotherapy in Advanced Endometrial Cancer

December 4th 2023

Experts review data on single-agent immunotherapy in patients with endometrial cancer from recent conferences, including ASCO 2023.

Expanding Horizons in Endometrial Cancer Treatment: Beyond Chemotherapy

December 4th 2023

Delve into the exciting developments in endometrial cancer treatment, including HER2 antibody drug conjugates, checkpoint inhibitors, and the promising impact of these therapies in the quest to reduce chemotherapy use.

Neoadjuvant Chemotherapy Does Not Give Survival Benefit Over Chemoradiation in Cervical Cancer

December 3rd 2023

Neoadjuvant chemotherapy preceding surgery did not result in a significant difference in 5-year overall survival rates compared with concomitant chemoradiotherapy in patients with stage IB2 to IIB cervical carcinoma, according to findings from the phase 3 EORTC-55994 trial.

The Role of dMMR in the Progression of Endometrial Cancer

November 29th 2023

David M. O’Malley, MD, details the definition of dMMR (mismatch repair deficiency), its prevalence in advanced endometrial cancer, and current treatment approaches for dMMR patients, with a focus on the potential for cure in recurrent/metastatic dMMR patients based on clinical trial data.

Shared Decision-Making in Advanced or Recurrent Endometrial Cancer

November 29th 2023

The panel discusses factors to consider when determining best treatment options for patients with recurrent or advanced endometrial cancer, including traditional clinical trial endpoints, cost, chance for cure versus disease control, and most importantly, patient preference.